


RealRate

PHARMACEUTICAL 2017

Cellectar Biosciences Inc. Rank 55 of 292







RealRate

Cellectar Biosciences Inc. Rank 55 of 292

The relative strengths and weaknesses of Cellectar Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Cellectar Biosciences Inc. compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 41% points. The greatest weakness of Cellectar Biosciences Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 26% points.

The company's Economic Capital Ratio, given in the ranking table, is 200%, being 197% points above the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	12,193
Cost of Goods Sold	0
Intangible Assets	1,675
Liabilities, Current	1,633
Liabilities, Non-Current	152
Other Assets	12
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	3,269
Other Revenues	0
Property and Equipment	1,444
Research and Development	4,750
Selling, General and Administrative Expense	4,699

Output Variable	Value in 1000 USD
Assets	15,325
Liabilities	1,785
Expenses	9,450
Revenues	0
Stockholders Equity	13,540
Net Income	-6,180
Comprehensive Net Income	-6,180
Economic Capital Ratio	200%

